Childhood Arthritis and Rheumatology Research Alliance Biologic Disease‐Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis

Objective The objective was to develop consensus treatment plans (CTPs) for patients with refractory moderately severe juvenile dermatomyositis (JDM) treated with biologic disease‐modifying antirheumatic drugs (bDMARDs). Methods The Biologics Workgroup of the Childhood Arthritis and Rheumatology Res...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis care & research (2010) 2024-11, Vol.76 (11), p.1532-1539
Main Authors: Tarvin, Stacey E., Sherman, Matthew A., Kim, Hanna, Balmuri, Nayimisha, Brown, Amanda G., Chow, Albert, Gewanter, Harry L., Guzman, Marietta M., Huber, Adam M., Kim, Susan, Klein‐Gitelman, Marisa S, Perron, Megan M., Robinson, Angela Byun, Sabbagh, Sara E., Savani, Sonia, Shenoi, Susan, Spitznagle, Jacob, Stingl, Cory, Syverson, Grant, Tory, Heather, Spencer, Charles, Aguiar Lapsia, Cassyanne L., Ardalan, Kaveh, Blier, Peter, Chang, Johanna, Chhabra, Amieleena, Cook, Kathryn, Curran, Megan, Fuller, Julie, Hui‐Yuen, Joyce, Lang, Bianca, Orandi, Amir B., Schmeling, Heinrike, Turnier, Jessica
Format: Article
Language:English
Subjects:
Arthritis
Children
Dermatomyositis
Infliximab
Monoclonal antibodies
Rheumatology
Rituximab
Tumor necrosis factor-α
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2203-6a9c822bfd0fbe1aed355daa1d9b93bdf0bcc35e0a97d071737fc2b10af47c8a3
container_end_page 1539
container_issue 11
container_start_page 1532
container_title Arthritis care & research (2010)
container_volume 76
creator Tarvin, Stacey E.
Sherman, Matthew A.
Kim, Hanna
Balmuri, Nayimisha
Brown, Amanda G.
Chow, Albert
Gewanter, Harry L.
Guzman, Marietta M.
Huber, Adam M.
Kim, Susan
Klein‐Gitelman, Marisa S
Perron, Megan M.
Robinson, Angela Byun
Sabbagh, Sara E.
Savani, Sonia
Shenoi, Susan
Spitznagle, Jacob
Stingl, Cory
Syverson, Grant
Tory, Heather
Spencer, Charles
Aguiar Lapsia, Cassyanne L.
Ardalan, Kaveh
Blier, Peter
Chang, Johanna
Chhabra, Amieleena
Cook, Kathryn
Curran, Megan
Fuller, Julie
Hui‐Yuen, Joyce
Lang, Bianca
Orandi, Amir B.
Schmeling, Heinrike
Turnier, Jessica
description Objective The objective was to develop consensus treatment plans (CTPs) for patients with refractory moderately severe juvenile dermatomyositis (JDM) treated with biologic disease‐modifying antirheumatic drugs (bDMARDs). Methods The Biologics Workgroup of the Childhood Arthritis and Rheumatology Research Alliance JDM Research Committee used case‐based surveys, consensus framework, and nominal group technique to produce bDMARD CTPs for patients with refractory moderately severe JDM. Results Four bDMARD CTPs were proposed: tumor necrosis factor α (TNFα) inhibitor (adalimumab or infliximab), abatacept, rituximab, and tocilizumab. Each CTP has different options for dosing and/or route. Among 76 respondents, consensus was achieved for the proposed CTPs (93% [67 of 72]) as well as for patient characteristics, assessments, outcome measures, and follow‐up. By weighted average, respondents indicated that they would most likely administer rituximab, followed by abatacept, TNFα inhibitor, and tocilizumab. Conclusion CTPs for the administration of bDMARDs in refractory moderately severe JDM were developed using consensus methodology. The implementation of the bDMARD CTPs will lay the groundwork for registry‐based prospective comparative effectiveness studies.
doi_str_mv 10.1002/acr.25393
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3073232018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3121785917</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2203-6a9c822bfd0fbe1aed355daa1d9b93bdf0bcc35e0a97d071737fc2b10af47c8a3</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhSNEJapLF7yBJTawuK1_bppkGVJ-1aroUiR2kWOPb1wldhk7RdnxCDwPj8OT4BDEAqmzmZHmm6OjOVn2jNFTRik_kwpPeS4q8Sg75ixn2915Xj7-N---PMlOQrilqQQvS1EdZz-b3g66916TGmOPNtpApNNk38M0yugHf5jJHgJIVD2ph8FKp4C8ssvGKnJh0yrAr-8_rry2ZrbuQGoXLa73C4HTgTTeBXBhCuQGQcYRXCQfB-kCMR6TvkGposeZJBVAGWGYySe4BwTyYboHZwcgF4CLo3H2YbH5NDsycghw8rdvss9vXt8077aX12_fN_XlVnFOxfZcVqrkvDOamg6YBC3yXEvJdNVVotOGdkqJHKisCk0LVojCKN4xKs2uUKUUm-zFqnuH_usEIbajDQqG5B78FFpBC8EFp6xM6PP_0Fs_oUvuWsE4K8q8Svqb7OVKKfQhIJj2Du0ocW4ZbZcg2xRk-yfIxJ6t7Lf0gflhsK2b_XrxGwCZpb0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3121785917</pqid></control><display><type>article</type><title>Childhood Arthritis and Rheumatology Research Alliance Biologic Disease‐Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Tarvin, Stacey E. ; Sherman, Matthew A. ; Kim, Hanna ; Balmuri, Nayimisha ; Brown, Amanda G. ; Chow, Albert ; Gewanter, Harry L. ; Guzman, Marietta M. ; Huber, Adam M. ; Kim, Susan ; Klein‐Gitelman, Marisa S ; Perron, Megan M. ; Robinson, Angela Byun ; Sabbagh, Sara E. ; Savani, Sonia ; Shenoi, Susan ; Spitznagle, Jacob ; Stingl, Cory ; Syverson, Grant ; Tory, Heather ; Spencer, Charles ; Aguiar Lapsia, Cassyanne L. ; Ardalan, Kaveh ; Blier, Peter ; Chang, Johanna ; Chhabra, Amieleena ; Cook, Kathryn ; Curran, Megan ; Fuller, Julie ; Hui‐Yuen, Joyce ; Lang, Bianca ; Orandi, Amir B. ; Schmeling, Heinrike ; Turnier, Jessica</creator><creatorcontrib>Tarvin, Stacey E. ; Sherman, Matthew A. ; Kim, Hanna ; Balmuri, Nayimisha ; Brown, Amanda G. ; Chow, Albert ; Gewanter, Harry L. ; Guzman, Marietta M. ; Huber, Adam M. ; Kim, Susan ; Klein‐Gitelman, Marisa S ; Perron, Megan M. ; Robinson, Angela Byun ; Sabbagh, Sara E. ; Savani, Sonia ; Shenoi, Susan ; Spitznagle, Jacob ; Stingl, Cory ; Syverson, Grant ; Tory, Heather ; Spencer, Charles ; Aguiar Lapsia, Cassyanne L. ; Ardalan, Kaveh ; Blier, Peter ; Chang, Johanna ; Chhabra, Amieleena ; Cook, Kathryn ; Curran, Megan ; Fuller, Julie ; Hui‐Yuen, Joyce ; Lang, Bianca ; Orandi, Amir B. ; Schmeling, Heinrike ; Turnier, Jessica ; for the Childhood Arthritis and Rheumatology Research Alliance Juvenile Dermatomyositis Workgroup</creatorcontrib><description>Objective The objective was to develop consensus treatment plans (CTPs) for patients with refractory moderately severe juvenile dermatomyositis (JDM) treated with biologic disease‐modifying antirheumatic drugs (bDMARDs). Methods The Biologics Workgroup of the Childhood Arthritis and Rheumatology Research Alliance JDM Research Committee used case‐based surveys, consensus framework, and nominal group technique to produce bDMARD CTPs for patients with refractory moderately severe JDM. Results Four bDMARD CTPs were proposed: tumor necrosis factor α (TNFα) inhibitor (adalimumab or infliximab), abatacept, rituximab, and tocilizumab. Each CTP has different options for dosing and/or route. Among 76 respondents, consensus was achieved for the proposed CTPs (93% [67 of 72]) as well as for patient characteristics, assessments, outcome measures, and follow‐up. By weighted average, respondents indicated that they would most likely administer rituximab, followed by abatacept, TNFα inhibitor, and tocilizumab. Conclusion CTPs for the administration of bDMARDs in refractory moderately severe JDM were developed using consensus methodology. The implementation of the bDMARD CTPs will lay the groundwork for registry‐based prospective comparative effectiveness studies.</description><identifier>ISSN: 2151-464X</identifier><identifier>ISSN: 2151-4658</identifier><identifier>EISSN: 2151-4658</identifier><identifier>DOI: 10.1002/acr.25393</identifier><language>eng</language><publisher>Boston, USA: Wiley Periodicals, Inc</publisher><subject>Arthritis ; Children ; Dermatomyositis ; Infliximab ; Monoclonal antibodies ; Rheumatology ; Rituximab ; Tumor necrosis factor-α</subject><ispartof>Arthritis care &amp; research (2010), 2024-11, Vol.76 (11), p.1532-1539</ispartof><rights>2024 American College of Rheumatology. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</rights><rights>2024 American College of Rheumatology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2203-6a9c822bfd0fbe1aed355daa1d9b93bdf0bcc35e0a97d071737fc2b10af47c8a3</cites><orcidid>0000-0003-3176-9958 ; 0000-0002-0595-6533 ; 0000-0003-4330-9692 ; 0000-0003-2159-8059 ; 0000-0002-2495-594X ; 0000-0002-5448-1538</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Tarvin, Stacey E.</creatorcontrib><creatorcontrib>Sherman, Matthew A.</creatorcontrib><creatorcontrib>Kim, Hanna</creatorcontrib><creatorcontrib>Balmuri, Nayimisha</creatorcontrib><creatorcontrib>Brown, Amanda G.</creatorcontrib><creatorcontrib>Chow, Albert</creatorcontrib><creatorcontrib>Gewanter, Harry L.</creatorcontrib><creatorcontrib>Guzman, Marietta M.</creatorcontrib><creatorcontrib>Huber, Adam M.</creatorcontrib><creatorcontrib>Kim, Susan</creatorcontrib><creatorcontrib>Klein‐Gitelman, Marisa S</creatorcontrib><creatorcontrib>Perron, Megan M.</creatorcontrib><creatorcontrib>Robinson, Angela Byun</creatorcontrib><creatorcontrib>Sabbagh, Sara E.</creatorcontrib><creatorcontrib>Savani, Sonia</creatorcontrib><creatorcontrib>Shenoi, Susan</creatorcontrib><creatorcontrib>Spitznagle, Jacob</creatorcontrib><creatorcontrib>Stingl, Cory</creatorcontrib><creatorcontrib>Syverson, Grant</creatorcontrib><creatorcontrib>Tory, Heather</creatorcontrib><creatorcontrib>Spencer, Charles</creatorcontrib><creatorcontrib>Aguiar Lapsia, Cassyanne L.</creatorcontrib><creatorcontrib>Ardalan, Kaveh</creatorcontrib><creatorcontrib>Blier, Peter</creatorcontrib><creatorcontrib>Chang, Johanna</creatorcontrib><creatorcontrib>Chhabra, Amieleena</creatorcontrib><creatorcontrib>Cook, Kathryn</creatorcontrib><creatorcontrib>Curran, Megan</creatorcontrib><creatorcontrib>Fuller, Julie</creatorcontrib><creatorcontrib>Hui‐Yuen, Joyce</creatorcontrib><creatorcontrib>Lang, Bianca</creatorcontrib><creatorcontrib>Orandi, Amir B.</creatorcontrib><creatorcontrib>Schmeling, Heinrike</creatorcontrib><creatorcontrib>Turnier, Jessica</creatorcontrib><creatorcontrib>for the Childhood Arthritis and Rheumatology Research Alliance Juvenile Dermatomyositis Workgroup</creatorcontrib><title>Childhood Arthritis and Rheumatology Research Alliance Biologic Disease‐Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis</title><title>Arthritis care &amp; research (2010)</title><description>Objective The objective was to develop consensus treatment plans (CTPs) for patients with refractory moderately severe juvenile dermatomyositis (JDM) treated with biologic disease‐modifying antirheumatic drugs (bDMARDs). Methods The Biologics Workgroup of the Childhood Arthritis and Rheumatology Research Alliance JDM Research Committee used case‐based surveys, consensus framework, and nominal group technique to produce bDMARD CTPs for patients with refractory moderately severe JDM. Results Four bDMARD CTPs were proposed: tumor necrosis factor α (TNFα) inhibitor (adalimumab or infliximab), abatacept, rituximab, and tocilizumab. Each CTP has different options for dosing and/or route. Among 76 respondents, consensus was achieved for the proposed CTPs (93% [67 of 72]) as well as for patient characteristics, assessments, outcome measures, and follow‐up. By weighted average, respondents indicated that they would most likely administer rituximab, followed by abatacept, TNFα inhibitor, and tocilizumab. Conclusion CTPs for the administration of bDMARDs in refractory moderately severe JDM were developed using consensus methodology. The implementation of the bDMARD CTPs will lay the groundwork for registry‐based prospective comparative effectiveness studies.</description><subject>Arthritis</subject><subject>Children</subject><subject>Dermatomyositis</subject><subject>Infliximab</subject><subject>Monoclonal antibodies</subject><subject>Rheumatology</subject><subject>Rituximab</subject><subject>Tumor necrosis factor-α</subject><issn>2151-464X</issn><issn>2151-4658</issn><issn>2151-4658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kc1u1TAQhSNEJapLF7yBJTawuK1_bppkGVJ-1aroUiR2kWOPb1wldhk7RdnxCDwPj8OT4BDEAqmzmZHmm6OjOVn2jNFTRik_kwpPeS4q8Sg75ixn2915Xj7-N---PMlOQrilqQQvS1EdZz-b3g66916TGmOPNtpApNNk38M0yugHf5jJHgJIVD2ph8FKp4C8ssvGKnJh0yrAr-8_rry2ZrbuQGoXLa73C4HTgTTeBXBhCuQGQcYRXCQfB-kCMR6TvkGposeZJBVAGWGYySe4BwTyYboHZwcgF4CLo3H2YbH5NDsycghw8rdvss9vXt8077aX12_fN_XlVnFOxfZcVqrkvDOamg6YBC3yXEvJdNVVotOGdkqJHKisCk0LVojCKN4xKs2uUKUUm-zFqnuH_usEIbajDQqG5B78FFpBC8EFp6xM6PP_0Fs_oUvuWsE4K8q8Svqb7OVKKfQhIJj2Du0ocW4ZbZcg2xRk-yfIxJ6t7Lf0gflhsK2b_XrxGwCZpb0</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Tarvin, Stacey E.</creator><creator>Sherman, Matthew A.</creator><creator>Kim, Hanna</creator><creator>Balmuri, Nayimisha</creator><creator>Brown, Amanda G.</creator><creator>Chow, Albert</creator><creator>Gewanter, Harry L.</creator><creator>Guzman, Marietta M.</creator><creator>Huber, Adam M.</creator><creator>Kim, Susan</creator><creator>Klein‐Gitelman, Marisa S</creator><creator>Perron, Megan M.</creator><creator>Robinson, Angela Byun</creator><creator>Sabbagh, Sara E.</creator><creator>Savani, Sonia</creator><creator>Shenoi, Susan</creator><creator>Spitznagle, Jacob</creator><creator>Stingl, Cory</creator><creator>Syverson, Grant</creator><creator>Tory, Heather</creator><creator>Spencer, Charles</creator><creator>Aguiar Lapsia, Cassyanne L.</creator><creator>Ardalan, Kaveh</creator><creator>Blier, Peter</creator><creator>Chang, Johanna</creator><creator>Chhabra, Amieleena</creator><creator>Cook, Kathryn</creator><creator>Curran, Megan</creator><creator>Fuller, Julie</creator><creator>Hui‐Yuen, Joyce</creator><creator>Lang, Bianca</creator><creator>Orandi, Amir B.</creator><creator>Schmeling, Heinrike</creator><creator>Turnier, Jessica</creator><general>Wiley Periodicals, Inc</general><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3176-9958</orcidid><orcidid>https://orcid.org/0000-0002-0595-6533</orcidid><orcidid>https://orcid.org/0000-0003-4330-9692</orcidid><orcidid>https://orcid.org/0000-0003-2159-8059</orcidid><orcidid>https://orcid.org/0000-0002-2495-594X</orcidid><orcidid>https://orcid.org/0000-0002-5448-1538</orcidid></search><sort><creationdate>202411</creationdate><title>Childhood Arthritis and Rheumatology Research Alliance Biologic Disease‐Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis</title><author>Tarvin, Stacey E. ; Sherman, Matthew A. ; Kim, Hanna ; Balmuri, Nayimisha ; Brown, Amanda G. ; Chow, Albert ; Gewanter, Harry L. ; Guzman, Marietta M. ; Huber, Adam M. ; Kim, Susan ; Klein‐Gitelman, Marisa S ; Perron, Megan M. ; Robinson, Angela Byun ; Sabbagh, Sara E. ; Savani, Sonia ; Shenoi, Susan ; Spitznagle, Jacob ; Stingl, Cory ; Syverson, Grant ; Tory, Heather ; Spencer, Charles ; Aguiar Lapsia, Cassyanne L. ; Ardalan, Kaveh ; Blier, Peter ; Chang, Johanna ; Chhabra, Amieleena ; Cook, Kathryn ; Curran, Megan ; Fuller, Julie ; Hui‐Yuen, Joyce ; Lang, Bianca ; Orandi, Amir B. ; Schmeling, Heinrike ; Turnier, Jessica</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2203-6a9c822bfd0fbe1aed355daa1d9b93bdf0bcc35e0a97d071737fc2b10af47c8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Arthritis</topic><topic>Children</topic><topic>Dermatomyositis</topic><topic>Infliximab</topic><topic>Monoclonal antibodies</topic><topic>Rheumatology</topic><topic>Rituximab</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tarvin, Stacey E.</creatorcontrib><creatorcontrib>Sherman, Matthew A.</creatorcontrib><creatorcontrib>Kim, Hanna</creatorcontrib><creatorcontrib>Balmuri, Nayimisha</creatorcontrib><creatorcontrib>Brown, Amanda G.</creatorcontrib><creatorcontrib>Chow, Albert</creatorcontrib><creatorcontrib>Gewanter, Harry L.</creatorcontrib><creatorcontrib>Guzman, Marietta M.</creatorcontrib><creatorcontrib>Huber, Adam M.</creatorcontrib><creatorcontrib>Kim, Susan</creatorcontrib><creatorcontrib>Klein‐Gitelman, Marisa S</creatorcontrib><creatorcontrib>Perron, Megan M.</creatorcontrib><creatorcontrib>Robinson, Angela Byun</creatorcontrib><creatorcontrib>Sabbagh, Sara E.</creatorcontrib><creatorcontrib>Savani, Sonia</creatorcontrib><creatorcontrib>Shenoi, Susan</creatorcontrib><creatorcontrib>Spitznagle, Jacob</creatorcontrib><creatorcontrib>Stingl, Cory</creatorcontrib><creatorcontrib>Syverson, Grant</creatorcontrib><creatorcontrib>Tory, Heather</creatorcontrib><creatorcontrib>Spencer, Charles</creatorcontrib><creatorcontrib>Aguiar Lapsia, Cassyanne L.</creatorcontrib><creatorcontrib>Ardalan, Kaveh</creatorcontrib><creatorcontrib>Blier, Peter</creatorcontrib><creatorcontrib>Chang, Johanna</creatorcontrib><creatorcontrib>Chhabra, Amieleena</creatorcontrib><creatorcontrib>Cook, Kathryn</creatorcontrib><creatorcontrib>Curran, Megan</creatorcontrib><creatorcontrib>Fuller, Julie</creatorcontrib><creatorcontrib>Hui‐Yuen, Joyce</creatorcontrib><creatorcontrib>Lang, Bianca</creatorcontrib><creatorcontrib>Orandi, Amir B.</creatorcontrib><creatorcontrib>Schmeling, Heinrike</creatorcontrib><creatorcontrib>Turnier, Jessica</creatorcontrib><creatorcontrib>for the Childhood Arthritis and Rheumatology Research Alliance Juvenile Dermatomyositis Workgroup</creatorcontrib><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Arthritis care &amp; research (2010)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tarvin, Stacey E.</au><au>Sherman, Matthew A.</au><au>Kim, Hanna</au><au>Balmuri, Nayimisha</au><au>Brown, Amanda G.</au><au>Chow, Albert</au><au>Gewanter, Harry L.</au><au>Guzman, Marietta M.</au><au>Huber, Adam M.</au><au>Kim, Susan</au><au>Klein‐Gitelman, Marisa S</au><au>Perron, Megan M.</au><au>Robinson, Angela Byun</au><au>Sabbagh, Sara E.</au><au>Savani, Sonia</au><au>Shenoi, Susan</au><au>Spitznagle, Jacob</au><au>Stingl, Cory</au><au>Syverson, Grant</au><au>Tory, Heather</au><au>Spencer, Charles</au><au>Aguiar Lapsia, Cassyanne L.</au><au>Ardalan, Kaveh</au><au>Blier, Peter</au><au>Chang, Johanna</au><au>Chhabra, Amieleena</au><au>Cook, Kathryn</au><au>Curran, Megan</au><au>Fuller, Julie</au><au>Hui‐Yuen, Joyce</au><au>Lang, Bianca</au><au>Orandi, Amir B.</au><au>Schmeling, Heinrike</au><au>Turnier, Jessica</au><aucorp>for the Childhood Arthritis and Rheumatology Research Alliance Juvenile Dermatomyositis Workgroup</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Childhood Arthritis and Rheumatology Research Alliance Biologic Disease‐Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis</atitle><jtitle>Arthritis care &amp; research (2010)</jtitle><date>2024-11</date><risdate>2024</risdate><volume>76</volume><issue>11</issue><spage>1532</spage><epage>1539</epage><pages>1532-1539</pages><issn>2151-464X</issn><issn>2151-4658</issn><eissn>2151-4658</eissn><abstract>Objective The objective was to develop consensus treatment plans (CTPs) for patients with refractory moderately severe juvenile dermatomyositis (JDM) treated with biologic disease‐modifying antirheumatic drugs (bDMARDs). Methods The Biologics Workgroup of the Childhood Arthritis and Rheumatology Research Alliance JDM Research Committee used case‐based surveys, consensus framework, and nominal group technique to produce bDMARD CTPs for patients with refractory moderately severe JDM. Results Four bDMARD CTPs were proposed: tumor necrosis factor α (TNFα) inhibitor (adalimumab or infliximab), abatacept, rituximab, and tocilizumab. Each CTP has different options for dosing and/or route. Among 76 respondents, consensus was achieved for the proposed CTPs (93% [67 of 72]) as well as for patient characteristics, assessments, outcome measures, and follow‐up. By weighted average, respondents indicated that they would most likely administer rituximab, followed by abatacept, TNFα inhibitor, and tocilizumab. Conclusion CTPs for the administration of bDMARDs in refractory moderately severe JDM were developed using consensus methodology. The implementation of the bDMARD CTPs will lay the groundwork for registry‐based prospective comparative effectiveness studies.</abstract><cop>Boston, USA</cop><pub>Wiley Periodicals, Inc</pub><doi>10.1002/acr.25393</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-3176-9958</orcidid><orcidid>https://orcid.org/0000-0002-0595-6533</orcidid><orcidid>https://orcid.org/0000-0003-4330-9692</orcidid><orcidid>https://orcid.org/0000-0003-2159-8059</orcidid><orcidid>https://orcid.org/0000-0002-2495-594X</orcidid><orcidid>https://orcid.org/0000-0002-5448-1538</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2151-464X
ispartof Arthritis care & research (2010), 2024-11, Vol.76 (11), p.1532-1539
issn 2151-464X
2151-4658
2151-4658
language eng
recordid cdi_proquest_miscellaneous_3073232018
source Wiley-Blackwell Read & Publish Collection
subjects Arthritis
Children
Dermatomyositis
Infliximab
Monoclonal antibodies
Rheumatology
Rituximab
Tumor necrosis factor-α
title Childhood Arthritis and Rheumatology Research Alliance Biologic Disease‐Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T03%3A14%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Childhood%20Arthritis%20and%20Rheumatology%20Research%20Alliance%20Biologic%20Disease%E2%80%90Modifying%20Antirheumatic%20Drug%20Consensus%20Treatment%20Plans%20for%20Refractory%20Moderately%20Severe%20Juvenile%20Dermatomyositis&rft.jtitle=Arthritis%20care%20&%20research%20(2010)&rft.au=Tarvin,%20Stacey%20E.&rft.aucorp=for%20the%20Childhood%20Arthritis%20and%20Rheumatology%20Research%20Alliance%20Juvenile%20Dermatomyositis%20Workgroup&rft.date=2024-11&rft.volume=76&rft.issue=11&rft.spage=1532&rft.epage=1539&rft.pages=1532-1539&rft.issn=2151-464X&rft.eissn=2151-4658&rft_id=info:doi/10.1002/acr.25393&rft_dat=%3Cproquest_cross%3E3121785917%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2203-6a9c822bfd0fbe1aed355daa1d9b93bdf0bcc35e0a97d071737fc2b10af47c8a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3121785917&rft_id=info:pmid/&rfr_iscdi=true